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Abstract. Background/Aim: Development of new potential
drugs to overcome multidrug resistance to chemotherapy is a
big challenge for cancer treatment. Attention is also given to
the natural compounds and their derivatives. The study aimed
at evaluating the impact of a new chalcone derivative (1C)
on multidrug resistant cell lines, focusing on P-glycoprotein
(P-gp, ABCB1) inhibition, as well as 1C-doxorubicin
interaction in vitro. Materials and Methods: Cytotoxic and
antiproliferative effects of the 1C compound were assessed
by thiazolyl blue tetrazolium bromide (MTT) method in
mouse T-cell lymphoma and human colon adenocarcinoma
cells expressing ABCB1. Alterations in ABCB1 activity were
evaluated by rhodamine 123 accumulation assay using flow
cytometry. Drug-drug interaction was studied using
combination assay. Results: Our results confirmed
antiproliferative, cytotoxic, as well as ABCB1 inhibitory
potential of 1C in both tested ABCB1-expressing cancer cell
lines. Furthermore, 1C displayed synergistic interaction with
doxorubicin. Conclusion: Our results suggest the 1C
chalcone derivative as a promising compound against
resistant lymphoma and colon cancer, which could be used in
monotherapy or in combination with other chemotherapeutics. 
Several studies in many cancers have shown an association
between overexpression of P-glycoprotein (P-gp, MDR1,
lately named as ABCB1) and resistance to a number of
structurally and functionally unrelated chemotherapeutics
(multidrug resistance) (1, 2). This membrane protein can
expel drugs from the cancer cells, preventing their
pharmacological action (3). Currently, many cytostatics are
considered as ABCB1 substrates (e.g. anthracyclines,
antimetabolites) (4). 
Until now, several ABCB1 inhibitors (e.g. verapamil,
tariquidar) have been discovered to increase the sensitivity
of multidrug-resistant cancer cells. However, due to their
poor potency, high risk of side effects, and adverse
interactions with concomitant chemotherapy, no ABCB1
inhibitor has been suitable for use in the clinic. Therefore,
many researchers have focused their attention on searching
for new molecules to overcome multidrug resistance (5-7).
Within the last years, interest intensified in the group of
natural phytochemicals and their derivatives as the fourth
generation of multidrug resistance reversal agents (4, 8).
Chalcones (1,3-diarylprop-2-en-1-ones) are precursors in the
biosynthesis of flavonoids with a wide spectrum of
biological activities (e.g. anti-inflammatory, antimicrobial,
anticancer) (9, 10) and they represent one of the promising
substances. Although their multidrug resistance reversal
effect and potential to modulate ABCB1 activity have been
evaluated in several cancer cell lines (11-18), their impact on
colon cancer has not been studied yet. 
In our recent study, we showed a strong antiproliferative
activity of the new synthetic acridine chalcone derivative 1C
on human colon adenocarcinoma cells and T-cell lymphoma
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(19). Therefore, the present work was focused on the
investigation of antiproliferative, cytotoxic, and ABCB1
inhibitory effects of this compound in human colon
adenocarcinoma cells and T-cell lymphoma cell lines
overexpressing ABCB1. Additionally, the type of in vitro
drug-drug interaction between compound 1C and
doxorubicin was assessed.
Materials and Methods
Tested compound. (2E)-3-(acridin-9-yl)-1-(2,6-dimethoxyphenyl)prop-
2-en-1-one (1C) was synthetized at the Faculty of Natural Sciences of
the P. J. Safarik University in Kosice. 
Cell lines. The ABCB1-expressing T-cell lymphoma cell line
(MDR) was obtained from parental L5178Y mouse T lymphoma
cells (PAR) (ECACC Cat. No. 87111908, FDA, Silver Spring, MD,
USA) after transfection with pHaMDR1/A retrovirus and culturing
of both cell lines, as previously described (7). The Colo 205,
doxorubicin-sensitive (CCL-222) and Colo 320/MDR1-LRP
multidrug resistant, overexpressing ABCB1-LRP (CCL-220.1)
human colon adenocarcinoma cell lines were purchased from LGC
Promochem (Teddington, UK). The cells were cultured in RPMI-
1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented
with 10% heat-inactivated foetal bovine serum (FBS; Sigma-
Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 1 mM Na-pyruvate,
100 mM HEPES (Sigma-Aldrich), nystatin and a penicillin-
streptomycin mixture (Sigma-Aldrich) at concentrations of 100 U/l
and 10 mg/l, respectively. The NIH/3T3 mouse embryonic fibroblast
cell line (ATCC CRL-1658) (LGC Promochem, Teddington, UK)
was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM;
Sigma-Aldrich), containing 4.5 g/l glucose, supplemented with 10%
heat-inactivated FBS, 2 mM L-glutamine (Sigma-Aldrich), 1 mM
Na-pyruvate (Sigma-Aldrich), nystatin (Sigma-Aldrich) and a
penicillin-streptomycin mixture (Sigma-Aldrich) in concentrations
of 100 U/l and 10 mg/l, respectively. The MRC-5 human embryonic
lung fibroblast cell line (ATCC CCL-171) (LGC Promochem,
Teddington, UK) was cultured in Eagle’s Minimal Essential
Medium (EMEM, Sigma-Aldrich), containing 4.5 g/l glucose,
supplemented with a non-essential amino acid (NEAA) mixture
(Sigma-Aldrich), a selection of vitamins and 10% heat-inactivated
FBS, 2 mM L-glutamine (Sigma-Aldrich), 1 mM Na-pyruvate
(Sigma-Aldrich), nystatin (Sigma-Aldrich) and a penicillin-
streptomycin mixture (Sigma-Aldrich) at concentrations of 100 U/l
and 10 mg/l, respectively. 
Cytotoxic and antiproliferative assay. The effects of decreasing
concentrations of the synthetic chalcone derivative 1C on cell growth
were determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl -
tetrazolium bromide (MTT) assay in 96-well cell culture microplates.
The maximum concentration of tested compound was 20 μM. Cells
(PAR, MDR, Colo 205 and Colo 320) were seeded at a density of
1×104 cells/well or 6×103 cells/well for cytotoxic and antiproliferative
assay, respectively. After a 24-h (cytotoxic assay) or 72-h
(antiproliferative assay) incubation at 37˚C, 20 μl of MTT (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) solution (5 mg/ml)
were added to each well. After an additional incubation at 37˚C for
4 h, 100 μl of 10% sodium dodecyl sulphate (SDS, Sigma-Aldrich
Chemie GmbH) were added to each well to dissolve the produced
formazan, and after 12 h optical density (OD) was measured.
Additionally to 1C, the effects of decreasing concentrations of
doxorubicin (TEVA Pharmaceuticals, Debrecen, Hungary; maximum
concentration 10 μM), verapamil (Sigma; maximum concentration
100 μM), which is known as ABCB1 substrate and inhibitor (20, 21),
and DMSO (Sigma-Aldrich Chemie GmbH; maximum concentration
1% v/v) on cell growth were evaluated. Cytotoxic assay was also
performed for the two non-cancerous cell lines NIH/3T3 and MRC-
5 (2×104 cells/well). Overall, the cell growth was then determined by
measuring the OD at 550 nm (ref. 630 nm) with a Multiscan EX
ELISA reader (Thermo Labsystems, Cheshire, WA, USA). Results
obtained from MTT assay were used to determine the percentage of
inhibition of cell growth. Absorbance of control wells (untreated
cells) was taken as 100%, and the inhibition of cell growth was
expressed as a percent of control. 
Flow cytometric analysis. The fluorescence-based rhodamine 123
accumulation assay was performed as previously described (7) in
order to investigate the activity of 1C as ABCB1 modulator on both
parental cancer cell lines (PAR, Colo 205) and the corresponding
ABCB1-overexpressing sublines (MDR, Colo 320). Cells were
adjusted to 2×106 cells/ml and tested compound was added (10 μl).
Different concentrations (0.5, 1, 2.5 and 10 μM) of 1C as well as
doxorubicin (5 μM) were tested. Verapamil (Sigma; 20 μM) used in
both cancer cell lines (MDR, Colo 320) served as reference inhibitor
(positive control). DMSO at 1 % v/v was used as solvent control.
Rhodamine 123 fluorescent dye (Sigma) was added to the samples
at a final concentration of 5.2 μM. The fluorescence of the cell
population was measured with a Partec CyFlow® flow cytometer
(Partec, Münster, Germany). The mean fluorescence and SD values
were calculated from three independent experiments. 
Drug combination assay. Serial dilutions of doxorubicin ranging
from 17.24 μM to 0.14 μM were made in a horizontal direction
(100 μl), while serial dilutions of the drug resistance modifier
were made vertically (50 μl), in a microtiter plate. The MDR and
Colo 320 cells were re-suspended in culture medium (6×103
cells/well) and seeded at a density 50 μl/well. The plates were
incubated for 72 h at 37˚C in a 5% CO2 incubator, and cell growth
was determined by the MTT assay. 
Statistical analysis. Results obtained from three independent MTT
measurements were used to determine a half maximal inhibitory
concentration (IC50) and the mean±SD for each cell line. The results
from rhodamine 123 assay were obtained from three independent
flow cytometry experiments, in which at least 20,000 individual
cells/measurement of the overall population were evaluated for
rhodamine 123 retention. The percentage of mean fluorescence
intensity was calculated for the treated MDR and Colo 320 cells as
compared with the untreated cells. Rhodamine 123 accumulation
was expressed as a fluorescence activity ratio (FAR) that was
calculated based on the equation mentioned previously (7). Drug
interactions were evaluated using CompuSyn software
(www.combosyn.com, ComboSyn, Inc., Paramus, NJ, USA).
Combination index (CI) values at 50% of the growth inhibition dose
(ED50) with corresponding SD values were determined using the
software to plot four to five data points to each ratio. CI values were
calculated by means of the median-effect equation, where CI<1,
CI=1, and CI>1 represent synergism, additive effect (or no
interaction), and antagonism, respectively (22). Student’s t-test
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(GraphPad Software, La Jolla, CA, USA) was employed to
determine statistical significance. Differences were considered
significant when p-values were lower than 0.05. 
Results
Effect of synthetic chalcone derivative 1C on cell growth. The
effect of the synthetic chalcone derivative 1C on cell growth
was determined on mouse T-cell lymphoma cells and human
colon adenocarcinoma cells expressing ABCB1 (MDR and
Colo 320) or not (PAR and Colo 205) by MTT analysis.
Overall, compared to the parental cell lines, 1C exerted weaker
cytotoxic effects on multidrug resistant cell lines; nevertheless,
1C compound was still effective on these sub-lines (PAR vs.
MDR: IC50 4.64 μM vs. 5.02 μM, p≥0.05; Colo 205 vs. Colo
320: IC50 9.20 μM vs. 10.97 μM, p≥0.05). Similarly,
antiproliferative activity was comparable (PAR vs. MDR: IC50
3.47 μM vs. 4.78 μM, p≥0.05; Colo 205 vs. Colo 320: IC50 3.84
μM vs. 4.49 μM, p≥0.05). On the other hand, in the cytotoxic
assay, verapamil (ABCB1 substrate, inhibitor or inducer) and
doxorubicin (ABCB1 substrate or inducer) (4) exhibited
significantly decreased inhibition of cell growth in the resistant
cell lines (p<0.001). All IC50 values obtained from MTT assays
(cytotoxic and antiproliferative) on cancer cell lines together
with IC50 of verapamil and doxorubicin are summarized in
Table I and Table II, respectively. Moreover, it was
demonstrated that 1C had significantly decreased inhibitory
effects on non-cancerous cell lines (mouse NIH/3T3 and human
MRC-5 cells) than on the tested cancer cell lines (p<0.001 or
p<0.01; Table III). DMSO did not show any inhibitory activity
on cell growth at a concentration of 1% v/v in all experiments. 
To sum up, in addition to potent cytotoxic and
antiproliferative effects on cell lines expressing ABCB1 or
not, the tested compound 1C showed lower toxicity against
non-cancer cells. 
Effect of synthetic chalcone derivative 1C on ABCB1
transporter. Due to the potent cell growth inhibitory effect of
1C on cell lines expressing ABCB1, we next analysed
whether compound 1C affects ABCB1 efflux activity in
cancer cells. Thus, rhodamine 123 accumulation assay was
performed using rhodamine 123 as an ABCB1-specific
substrate. Briefly, parental cells (PAR, Colo 205) and their
sub-lines expressing ABCB1 (MDR, Colo 320) were treated
with 1C, doxorubicin, as well as verapamil as positive control
and DMSO as negative control. The accumulation of
rhodamine 123 was evaluated by flow cytometry. The
resulting values of mean fluorescence intensity of the cells
(FL-1)±SD values and fluorescence activity ratio (FAR) are
summarized in Table IV (for mouse T-lymphoma cells) and
Table V (for human colon adenocarcinoma cells). The
potential of compounds to modulate ABCB1 was estimated
from FAR values, which were calculated using the formula
presented previously (7). Our compound 1C at concentrations
≥1 μM was able to significantly increase rhodamine 123
accumulation in MDR cell line, compared to untreated MDR
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Table I. Cytotoxic effect of tested compounds on different cell lines
[IC50 (μM)±SD].
Compound                                            Cell lines
                            PAR                 MDR            Colo 205        Colo 320
1C                    4.64±0.24         5.02±0.38        9.20±1.37     10.97±1.86
Verapamil        15.81±1.18   23.41±0.31***   43.21±2.28       >100***
Doxorubicin     0.49±0.04     11.15±0.56***    1.56±0.03    6.45±0.19***
PAR, Parental L5178Y mouse T-cell lymphoma cells; MDR, ABCB1-
transfected L5178Y cells. The results are presented from three
independent experiments. ***p<0.001 (MDR vs. PAR, Colo 320 vs.
Colo 205). 
Table II. Antiproliferative effect of tested compounds on different cell
lines [IC50 (μM)±SD].
Compound                                           Cell lines 
                            PAR                 MDR            Colo 205        Colo 320
1C                    3.47±0.40         4.78±0.71        3.84±0.25       4.49±0.42
Verapamil        24.13±1.41       25.82±0.28           >100               >100
Doxorubicin     0.03±0.01      0.39±0.04***     0.24±0.03      0.14±0.03*
PAR, Parental L5178Y mouse T-cell lymphoma cells; MDR, ABCB1-
transfected L5178Y cells. The results are presented from three
independent experiments. *p<0.05, ***p<0.001 (MDR vs. PAR, Colo
320 vs. Colo 205). 
Table III. Cytotoxic effect of tested compounds on non-cancerous and
cancer cell lines [IC50 (μM)±SD]. 
Compound                                           Cell lines 
                                NIH/3T3                     PAR                       MDR
1C                                 >20                 4.64±0.24***         5.02±0.38***
Verapamil                    >100               15.81±1.18***       23.41±0.31***
Doxorubicin            5.71±0.50            0.49±0.04***        11.15±0.56***
                                  MRC-5                  Colo 205                Colo 320
1C                                 >20                 9.20±1.37***        10.97±1.86**
Verapamil                    >100               43.21±2.28***            >100***
Doxorubicin                 >10                 1.56±0.03***         6.45±0.19***
PAR, Parental L5178Y mouse T-cell lymphoma cells; MDR, ABCB1-
transfected L5178Y cells. The results are presented from three
independent experiments. **p<0.01, ***p<0.001 (PAR/MDR vs.
NIH/3T3, Colo 205/Colo 320 vs. MRC-5).
cells (1 μM: p<0.01, 2.5 μM: p<0.001, and 10 μM: p<0.001)
(Table IV). A similar effect of 1C-induced increase in
rhodamine 123 accumulation was observed in Colo 320 cells
treated with 1C, compared to the same untreated cell line (0.5
μM: p<0.05, 1, 2.5, and 10 μM: p<0.001) (Table V).
Moreover, accumulation of rhodamine 123 was significantly
higher in 1C-treated resistant cancer cell lines in comparison
with the same cell lines treated with verapamil (MDR:
p<0.001 at concentration of 1C≥2.5 μM, p<0.01 at
concentration of 1C=1 μM; Colo320: p<0.001 at
concentration of 1C=10 μM, p<0.01 at concentration of
1C=2.5 μM) (Table IV and Table V). 
Overall, the tested chalcone 1C enhanced accumulation of
known ABCB1 substrate (rhodamine 123) more strongly
than verapamil. 
Combination assay between synthetic chalcone derivative 1C
and doxorubicin. In order to find out the type of in vitro
drug-drug interaction between the compound 1C and the
cytostatic drug doxorubicin (known ABCB1 substrate) (23),
a combination assay was carried out on the resistant MDR
and Colo 320 cell lines. Several concentrations of the
compound 1C and doxorubicin were assessed. The type of
interaction between tested substances was calculated and
expressed using the combination index (CI) value±standard
deviation. Tested chalcone derivative displayed synergistic
interaction with doxorubicin, being able to enhance
inhibition of cell growth of both drug-resistant cancer cell
lines (MDR: CI at ED50=0.62, Colo 320: CI at ED50=0.50).
The best combination ratios between 1C and doxorubicin
were also determined (Table VI).
In conclusion, the tested chalcone increased cell growth
inhibition of doxorubicin in both tested cell lines.
Discussion
To our knowledge, this is the first study that assessed ABCB1
reversal effect of chalcone derivative in human colon
adenocarcinoma cells, in addition to the effect on mouse T-
lymphoma cells that has been tested (14). The choice of
tested cancer cell lines (PAR, MDR, Colo 205 and Colo 320)
and selection of chalcone derivative was in accordance to our
recent study, which demonstrated a strong antiproliferative
activity of the chalcone derivative 1C in human colorectal
HCT116 cells and human T-cell lymphoma (19). 
In the present work, we found that compound 1C had
potent antiproliferative and cytotoxic effects on parental
cancer cell lines (PAR, Colo 205), as well as on their
resistant sub-lines expressing ABCB1, with comparable IC50
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Table VI. The type of interaction between the synthetic chalcone
derivative 1C and doxorubicin.
Cell lines          Best ratio1        CI at ED502          SD            Interaction
MDR                    4.64:1                   0.62                0.09           Synergism
Colo 320              4.64:1                   0.50                0.07           Synergism
1Data are shown as the best combination ratio between 1C and
doxorubicin. 2Combination index (CI) values at the 50% growth
inhibition dose (ED50) were determined by the CompuSyn software to
plot four to five data points at each ratio. CI values were calculated by
means of the median-effect equation, where CI<1, represent synergism.
MDR, ABCB1-transfected L5178Y mouse T-cell lymphoma cells; SD,
standard deviation.
Table IV. Rhodamine 123 accumulation in mouse T-lymphoma cells.
Samples                       Concentration        FL-1±SD                 FAR
                                            (μM)
Untreated PAR                       -                 92.60±1.40                    -
Untreated MDR                     -                   0.52±0.02                   1
Treated MDR                                                                                  
  Verapamil                            20                 0.99±0.05                 1.90***
  Doxorubicin                          5                 0.82±0.03                 1.58***
  1C                                       0.5                 9.58±6.72                     18.42
  1C                                          1               23.10±5.12            44.42** ++
  1C                                       2.5               66.60±1.57      128.08*** +++
  1C                                        10               92.20±4.72      177.31*** +++
  DMSO (% v/v)                  1.0                 0.44±0.13                       0.85
FL-1, Mean fluorescence intensity of the cells; SEM, standard error of
the mean; FAR, fluorescence activity ratio, PAR, parental L5178Y
mouse T-cell lymphoma cells; MDR, ABCB1-transfected L5178Y cells.
All data represent the means±SD of three independent experiments.
**p<0.01, ***p<0.001 (treated MDR vs. untreated MDR); ++p<0.01,
+++p<0.001 (1C vs. verapamil).
Table V. Rhodamine 123 accumulation in human colon adenocarcinoma
cells. 
Samples                       Concentration        FL-1±SD                     FAR
                                            (μM)
Untreated Colo 205                 -               96.20±5.05                             -
Untreated Colo 320                 -                 1.95±0.47                             1
Treated Colo 320                                                                                      
Verapamil                               20               13.50±3.40                   6.92**
Doxorubicin                             5                 1.78±0.08                       0.91
  1C                                       0.5                 9.93±3.51                     5.90*
  1C                                          1               18.60±3.12                 9.54***
  1C                                       2.5               29.50±2.87          15.13*** ++
  1C                                        10               61.50±5.20        31.54*** +++
DMSO (% v/v)                     1.0                 1.45±0.52                       0.74
FL-1, Mean fluorescence intensity of the cells; SEM, standard error of
the mean; FAR, fluorescence activity ratio. All data represent the
means±SD of three independent experiments. *p<0.05, **p<0.01,
***p<0.001 (treated Colo 320 vs. untreated Colo 320); ++p<0.01,
+++p<0.001 (1C vs. verapamil). 
values. Therefore, our findings suggest that expression of
ABCB1 was not able to abolish the cytotoxic effect of 1C.
The important factor influencing the cytotoxicity of
chalcones against multidrug resistant cancer cell lines is
considered to be a presence of a methoxy substituent in the
scaffold, whereas chalcones with two methoxy groups show
better activity than chalcones with only one (24). The fact
that chalcone 1C contains two methoxy groups may be
critical for the mediation of its strong antiproliferative
activity toward the tested cell lines. Previous studies have
demonstrated inhibition of cell growth induced by methoxy
chalcones in cells from various cancer types (e.g. synovial
sarcoma, prostate cancer, colon cancer, bladder cancer, and
human oral squamous cell carcinoma) (25, 26), as well as in
multidrug resistant cells (mouse T-cell lymphoma-L5178,
human leukemia-CEM/ADR5000 or colon cancer-LoVo/DX)
(14, 24, 27). 
Interestingly, toxicity of 1C against non-cancerous mouse
NIH/3T3 and human MRC-5 cells was markedly reduced,
which is a crucial parameter to ensure safety of anticancer
treatment. Such a preferential action of chalcones against
cancer cells and not non-cancer cells has also been
documented in other studies (26, 28-30). 
Furthermore, our analysis showed that 1C could inhibit
ABCB1 mediated efflux of rhodamine 123 (ABCB1
substrate). In line with our findings, there are several
additional studies reporting the ability of chalcones to bind
to ABCB1 and inhibit its transport activity (12, 31).
Multidrug resistance reversal activity of chalcones, including
inhibition of other membrane transporters, has been
previously demonstrated for example in human breast cancer
(15, 32, 33) or human glioblastoma cells (13). Herein, the
tested chalcone 1C was even more potent inhibitor of
ABCB1 than verapamil. In literature, other chalcones have
been shown to inhibit ABCB1 activity more potently than
verapamil (14, 15). The precise mechanism by which
chalcones inhibit ABCB1 is still not fully understood;
however, according to several authors, chalcones can overlap
two binding sites of the nucleotide-binding domain (NBD2)
of ABCB1 (17, 34). The key factors influencing ABCB1
inhibitory activity of chalcones are believed to be
lipophilicity as well as the size and shape of molecules (17).
Structure-activity relationship (SAR) studies have shown that
the presence of methoxy groups (-OCH3) on ring A or basic
functional groups (i.e. nitrogen-containing heterocycles) on
ring B of chalcone scaffold is favourable for an interaction
with ABCB1 (12, 13, 16, 35). The substitution of ring A by
two methoxy groups and ring B by a basic acridine group in
1C molecule probably played an important role in facilitation
of ABCB1 inhibition; however, further experiments are
necessary to clarify the precise mechanism of its action. 
Combination therapy in cancer treatment is an essential
approach used to reduce drug resistance (36). Thus, in order
to know the type of drug-drug interaction at the cellular
level, in vitro combination chemotherapy model was
performed. Compound 1C was combined with the anticancer
drug doxorubicin, a well-known ABCB1 substrate and
inducer. Herein, we observed that the tested chalcone
derivative displayed synergistic interaction with doxorubicin
leading to enhancement of cell growth inhibition in both
cancer cell lines expressing ABCB1. Similarly, Arianingrum
et al. observed synergistic effects of a synthetic chalcone
with doxorubicin in breast cancer cells (37), while another
synthetic chalcone was shown to sensitize epithelial cancer
to cisplatin also displaying synergism (38). However, pre-
clinical in vivo studies are needed to evaluate drug-drug
interactions because of a greater impact of ABCB1 on drug
intestinal absorption and distribution.
To conclude, results presented here demonstrated dual
potential of the chalcone 1C to act as a chemotherapeutic, as
well as a chemosensitizing agent in resistant T-cell
lymphoma and colon cancer, even with higher sensitivity for
cancer cells. Furthermore, due to the ABCB1 inhibitory
activity, the compound could be potentially used as an
ABCB1 inhibitor in lab analyses.
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